Upstate Active Clinical Trials
Study Title:
A Phase 2/3Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK) Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered with an Optimized Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Viroligically Suppressed Pediatric Subjects.What is the purpose of the study? (in Layman's terms, please describe the study)
To evaluate the steady state pharmacokinetics (PK) and confirm the dose of cobicistat-boosted atazanavir (ATV/co) or cobicistat-boosted Darunavir (DRV/co) in HIV-1 antiretroviral experienced pediatric participants between the ages of 3 Months and less than 18 Years.Upstate Institutional Review Board (IRB) Number:
518998Study/Protocol ID:
GS-US-216-0128Study Phase:
2/3Patient Age Group:
ChildrenPrincipal Investigator:
Leonard B WeinerClinicalTrials.Gov ID:
NCT02016924For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Wendy A Holz
Phone: 315-464-7562
Email: [email protected]